兰索拉唑和泮托拉唑治疗十二指肠溃疡出血的最小成本分析

Cost minimization analysis of lansoprazole and pantoprazole in the treatment of duodenal ulcer hemorrhage

目的:考察兰索拉唑和泮托拉唑治疗十二指肠溃疡并出血患者临床疗效,并对两种治疗方案进行最小成本分析。方法:将60例十二指肠溃疡并出血的患者按照治疗方案,分为兰索拉唑治疗组30例,泮托拉唑治疗组30例,2组均未使用其他抑制胃酸分泌的药物。观察2组的临床疗效,不良反应发生率,并进行经济学分析。结果:2组治疗方案的临床有效率分别为93.33%和96.67%,无统计学意义。不良反应发生率经检验后亦无统计学意义(P>0.05),因此采用最小成本分析法进行经济学评价。兰索拉唑治疗组和泮托拉唑治疗组的成本分别为11 611.60元、13 445.09元。结论:兰索拉唑和泮托拉唑治疗十二指肠溃疡并出血症状疗效和安全性均较好,但相较于泮托拉唑,使用兰索拉唑治疗成本更低、经济性更好,临床可根据患者实际情况选择用药。

OBJECTIVE To evaluate the clinical efficacy of lansoprazole and pantoprazole in the treatment of duodenal ulcer hemorrhage, and to conduct cost effectiveness analysis. METHODS Sixty patients with duodenal ulcer hemorrhage were divided into lansoprazole group （30 patients） and pantoprazole group （30 patients）. Clinical efficacy and adverse drug reactions （ADRs） of the two groups were analyzed, and cost minimization analysis was also conducted. RESULTS Clinical effective rates were 93.33% and 96.67% in lansoprazole group and pantoprazole group, respectively. The incidences of ADRs were 6.67% and 13.33% （P〉0.05）. Cost minimization analysis was used for economic evaluation. The costs of lansoprazole and pantoprazole groups were 11 611.60 yuan and 13 445.09 yuan. Sensitivity analysis supported the results. CONCLUSION Lansoprazole and pantoprazole show good therapeutic efficacy and safety in the treatment of duodenal ulcer hemorrhage. Compared to pantoprazole, lansoprazole has lower cost and better economics in the treatment. The drugs should be chosen according to disease conditions.